bioMerieux (BMXMF)
(Delayed Data from OTC)
$122.50 USD
0.00 (0.00%)
Updated Sep 13, 2024 10:22 AM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Cash flow Statements
Fiscal Year End for bioMerieux falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 349.37 | 464.11 | 707.73 | 460.00 | 302.06 |
Depreciation/Amortization & Depletion | 236.37 | 221.26 | 273.30 | 240.80 | 212.24 |
Net Change from Assets/Liabilities | -220.03 | -164.26 | -43.06 | -92.18 | -74.93 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 116.35 | -20.55 | 21.65 | 57.00 | 17.47 |
Net Cash From Operating Activities | 482.06 | 500.57 | 959.61 | 665.73 | 456.85 |
Property & Equipment | -359.22 | -283.73 | -319.56 | -288.77 | -286.05 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 1.95 | -56.68 | -0.47 | -2.63 | -2.69 |
Other Investing Activities | -171.76 | -215.99 | -43.54 | -11.54 | -27.33 |
Net Cash from Investing Activities | -529.03 | -556.41 | -363.57 | -302.94 | -316.06 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 13.75 | -165.63 | -4.50 | -21.02 | 0.00 |
Issuance (Repayment) of Debt | -37.66 | 15.07 | -59.27 | -153.64 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | -108.45 | -106.62 | -86.48 | -25.70 | -46.26 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | -0.91 | -103.82 |
Net Cash from Financing Activities | -132.37 | -257.29 | -150.25 | -201.27 | -149.97 |
Effect of Exchange Rate Changes | -32.14 | 40.77 | 46.38 | -38.95 | -6.83 |
Net Change In Cash & Equivalents | -211.37 | -272.46 | 492.17 | 122.57 | -15.90 |
Cash at Beginning of Period | 572.21 | 829.50 | 439.29 | 301.57 | 311.58 |
Cash at End of Period | 360.84 | 557.04 | 931.45 | 424.14 | 295.68 |
Diluted Net EPS | 3.26 | 4.02 | 5.99 | 3.90 | 2.58 |
Fiscal Year End for bioMerieux falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | NA | 349.37 | NA | 151.24 |
Depreciation/Amortization & Depletion | NA | NA | 236.37 | NA | 112.31 |
Net Change from Assets/Liabilities | NA | NA | -220.03 | NA | -163.56 |
Net Cash from Discontinued Operations | NA | NA | 0.00 | NA | NA |
Other Operating Activities | NA | NA | 116.35 | NA | 61.17 |
Net Cash From Operating Activities | NA | NA | 482.06 | NA | 161.27 |
Property & Equipment | NA | NA | -359.22 | NA | -160.83 |
Acquisition/ Disposition of Subsidiaries | NA | NA | 0.00 | NA | NA |
Investments | NA | NA | 1.95 | NA | 0.87 |
Other Investing Activities | NA | NA | -171.76 | NA | NA |
Net Cash from Investing Activities | NA | NA | -529.03 | NA | -160.07 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | NA | 13.75 | NA | 18.86 |
Issuance (Repayment) of Debt | NA | NA | -37.66 | NA | -25.30 |
Increase (Decrease) Short-Term Debt | NA | NA | 0.00 | NA | NA |
Payment of Dividends & Other Distributions | NA | NA | -108.45 | NA | -109.26 |
Other Financing Activities | NA | NA | 0.00 | NA | NA |
Net Cash from Financing Activities | NA | NA | -132.37 | NA | -115.69 |
Effect of Exchange Rate Changes | NA | NA | -32.14 | NA | -25.08 |
Net Change In Cash & Equivalents | NA | NA | -211.37 | NA | -139.57 |
Cash at Beginning of Period | NA | NA | 572.21 | NA | 576.49 |
Cash at End of Period | NA | NA | 360.84 | NA | 436.92 |
Diluted Net EPS | NA | NA | NA | NA | NA |